Abstract. In an attempt to identify B cell specific antigens, we have generated a mouse monoclonal antibody, R2D6, which is directed against plasma membranes of rat pancreatic B ofthe DME, developed in 60:40:9 chloroform/methanol/ 2.5 N ammonia, Ag(R2D6) migrated with a relative mobility (Rf) of 0.54±0.07 (n = 3), which was a position nearly coincident with the purified brain ganglioside, GD1a. The antigen bound to DEAE-Sephacel, was not inactivated by mild treatment with base (which hydrolyzes phospholipids) and eluted in ganglioside fractions upon C18 Sep-Pak and upon silicic acid chromatography. Hence, the solubility characteristics, enzyme sensitivities, and behavior of Ag(R2D6) in four chromatography systems are consistent with its identification as a ganglioside.
Introduction
The coexistence with insulin-dependent diabetes mellitus (IDDM)' of an autoimmune process directed against pancreatic islets of Langerhans has been well documented. Islet cell surface antibodies are immunocytochemically detectable in the sera of 67-82% of recent-onset IDDM patients (1) (2) (3) . Islet cell surface antibodies can be cytotoxic to B cells (4) and may alter glucosestimulated insulin release (5) , so that these circulating autoantibodies may be direct effectors of B cell destruction in IDDM or, instead, reflect some other unknown pathogenetic mechanism.
The problem of identifying B cell specific antigens, i.e., cell surface molecules of potential significance in the autoimmune pathogenesis of IDDM, has not yet been successfully approached. In an attempt to identify target antigens that were recognized by islet cell antibodies, Baekkeskov et al. (6) did immunoprecipitate 64,000-and 38,000-mol wt proteins from human islet preparations using sera from patients with IDDM. However, it was not shown that the antigens precipitated were specific either for endocrine cells or for the cell surface. An alternative approach is to generate mouse monoclonal antibodies against islet cells.
Although two monoclonal antibodies that recognize pancreatic islet cells have been generated previously by Eisenbarth et al. (7) (8) (9) , one (A2B5) was raised against glutaraldehyde-fixed chicken embryo retinal cells, whereas the other (A 1D2) was produced using a rat islet-cell tumor cell line, RINm5F, as the immunogen. These monoclonal antibodies are not B cell specific within the pancreas, since they recognize plasma membrane determinants shared by B, A, and D cells of pancreatic islets (reference 9, and present study).
In the present study, we report on the generation and characterization of a monoclonal antibody, R2D6, raised against normal Wistar-Furth islet cells, which recognizes a B cell specific plasma membrane ganglioside antigen. We also report on the utilization of this antibody for purification of pancreatic B and A cells by fluorescence-activated cell sorting.
Methods
Sources. Reagents were obtained from the following sources: culture medium RPMI 1640, Ham in CB for 1 h, washed in CB, dehydrated through a graded ethanol series and propylene oxide, and then were embedded in Araldite. Silver sections were cut on a diamond knife, mounted on carboncoated copper slotgrids, and were stained with uranyl acetate followed by lead citrate. All cells in each section were photographed, using a Philips 301 electron microscope (Philips Electronic Instruments, Mahwah, NJ) at 60 kV with a 30 ,um objective aperture. Montages of each section were then constructed and used to classify celltypes based on the ultrastructural characteristics of the secretory granules. Each ultrathin section that was analyzed was at least 20 Mm from any other section from the same block and sections were taken throughout the thickness of each block. These methods of analysis ensured that no cell was counted more than once and that the entire pellet was sampled.
Chromium (5"Cr) release assay. The 5"Cr release assay was performed as described (21) min. 150 ,A of fresh MEM was then added, and after centrifugation the supernatant was harvested with a Titertek collection system and counted in a gamma counter. The percentage of specific chromium release was then calculated.
Electron microscopic immunocytochemistry. The antigen recognized by R2D6 was localized by indirect immunoperoxidase labeling of islets using a modification of previously published procedures (22) . Freshly isolated islets were partially dispersed to allow adequate access of antibodies to all cell surfaces, and then washed free of serum in RPMI-1640. Cells from 100 islets were then incubated 45 min at room temperature in 30 p1 diluted R2D6 ascites (1:5 in RPMI-1640 containing 0.02% NaN3). Controls consisted of islet cells incubated in media containing either no antibody or an irrelevant monoclonal IgM antibody, A5H5. All samples were washed three times in RPMI/NaN3 and then incubated for 45 min in 30 ,l diluted peroxidase-conjugated goat antimouse immunoglobulins (1:5 in RPMI/NaN3). The cells were next washed three times in RPMI/NaN3, fixed in 2.5% glutaraldehyde/0.1 M sodium CB, and then washed three times in 0.1 M CB. The diaminobenzidine reaction was then carried out to allow ultrastructural localization ofantibody binding. All samples were then washed, postfixed, dehydrated, embedded, and sectioned, as described above for sorted cells. Sections were photographed unstained in a Philips 301 electron microscope (Philips Electronic Instruments) at 60 kV with a 30-Mm objective aperture.
Antigen identification
Enzyme sensitivities. Dispersed islet cells (750,000-900,000) were incubated at 370C for 15 min (with shaking) with 500 Ag enzyme/ml PBS for pronase (pH 7.5), papain (pH 7.0 or 6.0), trypsin (pH 7.5), ficin (pH 6.0), or chymotrypsin (pH 7.4), or for I h with protease-, aldolase-, and lecithinase-fiee neuraminidase (1 U/ml PBS, pH 6.0). Control incubations were performed with buffer at the same pH as each enzyme. All cells were washed three times in RIA buffer and R2D6-binding was assessed in a cell-binding assay as described above.
Immunoadsorption ofradiolabeled islet proteins. Rat islet cell surface proteins were radioiodinated by the method of Hubbard and Cohn (23), or cellular proteins were labeled metabolically by 35S-methionine incorporation after the method ofHughes and August (24) . Labeled membrane proteins were then solubilized in NP40, immunoadsorbed with R2D6, using the method of Lampson (25) , and then analyzed by SDS polyacrylamide gel electrophoresis (26) .
Immunoblotting of unlabeled islet protein. Unlabeled rat islet cell proteins were subjected to SDS-polyacrylamide gel electrophoresis (under nonreducing conditions), which was followed by electrophoretic transfer to nitrocellulose paper and by immunoautoradiographic detection of antigens with R2D6; the methods developed by Erickson et al. (27) were used.
Solvent extraction. Islets were washed in PBS and then homogenized as a pellet with three rapid passes of a 1-ml Thomas Teflon pestle homogenizer (100 Mm clearance). The homogenate was then extracted with 2:1 (v/v) chloroform/methanol (2 ml/4,000 islets) and sonicated in a Labline Ultratip sonicator (model 9100) at maximum power for 15 s. The extracted islets were pelleted at 2,000 g for 10 min, the supematant saved, and the pellet was reextracted twice (1 ml/4,000 islets). The three supernatants were pooled, dried under nitrogen gas, and immediately redissolved (with sonication) in either methanol or PBS, pH 7.4 (50 Ml/extract from 100 islets) and stored at 4°C. All steps were performed in glass vessels. Dichloromethane was used instead of chloroform after preliminary studies showed that R2D6-binding properties of the dried and redissolved dichloromethane/methanol extract (DME)
were indistinguishable from those of the chloroform/methanol extract. The DME was adsorbed to PVC plates (37°C for 1 h) and tested for R2D6-binding by solid-phase RIA as described above. The adsorbed DME was also tested for enzyme sensitivity of R2D6-binding. DME was adsorbed to PVC microtiter wells as above and then incubated with either Pronase (500 Mg/ml PBS, pH 7.4) at 60°C for 24 h, neuraminidase (I U/ml PBS, pH 6.0) at 37°C for 2 h, or appropriate buffer controls.
Chromatography. The DME was subjected to mild base hydrolysis and was fractionated on a C-18 Sep-Pak reverse-phase high performance liquid chromatography cartridge using the method described by Kundu and Suzuki (28). The hydrolysate was applied to the cartridge in water, washed with methanol, and the ganglioside fraction was eluted with chloroform/methanol (2:1). DEAE-Sephacel chromatography was performed by the method of Magnani (29) . The DME was applied to the column (1 X 2 cm) in chloroform/methanol/water (30:60:8) . The column was washed with 50 ml of solvent and the ganglioside fraction was eluted with 20 ml of 0.2 M ammonium acetate in methanol. The pooled void volume fractions and acetate fractions were separately concentrated. The acetate fractions were desalted on a Sephadex LH-20 column (0.5 X 10 cm) in methanol and each 2-ml fraction was dried under N2. The pooled DEAE void fractions and each LH-20 fraction were then tested for binding activity using the solid-phase assay. All activity was recovered in the LH-20 void fractions. Silicic acid chromatography was performed also by the method of Magnani (29) . A (0.5 X 2 cm) column of BioSil HA was washed with 100 ml of chloroform/methanol (2:1) and the DME was applied in the same solvent. The column was washed with 20 ml of solvent and the ganglioside fraction was eluted with 20 ml methanol. The void and methanol fractions were separately pooled, evaporated, and assayed for binding activity. In all three fractionation experiments, 0.1 mg of mixed brain gangliosides was added to the DME as carrier. High performance thin-layer chromatography plates were prerun, before sample loading, in the developing solvent (60:40:9 chloroform/methanol/2.5 N ammonia) and were dried thoroughly. DME from 200 rat islets was dried under nitrogen gas, redissolved (with sonication) in 10 Ml chloroform/methanol (2:1), and spotted across a 5-mm line (200 nl/spot) which was 1.0 cm from the bottom edge ofan HPTLC plate that was then developed. The separation was terminated when the solvent front was 2-3 mm from the top of the plate. The plate was divided into 5-mm sections (1.5 cm wide), and each section of silica gel was scraped. Each section was suspended by sonication in 400 Ml methanol. The silica gel was removed by filtration through a Millex GV filter. The eluted samples were dried, redissolved, and sonicated in 200 ,Ml methanol, and adsorbed onto PVC wells (50 MI/well) for solid-phase RIA of R2D6-binding activity, as described above. Purified brain gangliosides were used as standards by spotting 5 Mg in parallel lanes on the HPTLC plate. After development, the plate was broken in half and the side containing the standards was stained with I2.
Glucose-stimulated insulih release. Adult Wistar-Furth pancreatic islets, isolated by collagenase digestion, were preincubated at 5.6 mM glucose in TCM 199 medium for 18 h. Washed batches of 10 islets/3.5-mm dish were then incubated in 5.6 or 16.5 mM glucose with B5C2 (an irrelevant antibody) or R2D6 for 2 h. Insulin released into media was determined by RIA. In order to ensure adequate access of R2D6 to B cell surfaces, we performed similar experiments using monolayer cultures of rat islets. Adult Wistar-Furth islets were also dispersed by trypsin (0. I%)/EGTA (3 mM) into single cells and plated (20,000 cells/ 135-mm tissue culture dish) in TCM 199, which contained 11 mM glucose and 0.1 mM 3-isobutyl-I-methylxanthine. The single cells reaggregated and formed monolayers after 4 d, and these were used to determine whether R2D6 affected glucose-mediated insulin release.
Results
Production ofmonoclonal antibody R2D6. The spleen cells from BALB/c mice that were immunized with Wistar-Furth islet cells were fused with the myeloma cell line SP2/0-Agl4. Initial screening ofculture supernatants from the resulting hybridomas was performed on Wistar-Furth islet cells, rat skin fibroblasts, RINm5F cells, rat splenic leukocytes, and rat red blood cells by cell-binding RIA. One hybridoma showed binding to islet cells alone and was cloned twice by limiting dilution. The resulting clone was designated R2D6-5.3 and will be referred to as R2D6. After rescreening this clone to confirm its specificity, as described above, the clone was expanded in culture and then injected into Pristane-primed mice to induce ascites fluid formation. The R2D6 isotype was identified as IgM(k) by solidphase RIA. Partially purified antibodies or ascites were used as the source of antibodies for the experiments described in this report. Glucose-stimulated insulin release after R2D6-binding. Adult rat islets were incubated in 5.6 or 16.5 mM glucose with R2D6 or P3, and insulin that was released into the media was determined by RIA. R2D6 did not alter glucose-mediated insulin release under these conditions. In order to ensure adequate access of R2D6 to B cell surfaces, we performed similar experiments using monolayer cultures of adult rat islets. R2D6 still had no effect on insulin release in response to glucose. R2D6-binding to the cell surfaces of these monolayer cultures was confirmed by immunofluorescence.
Direct-blocking assays. The relationship of the antigenic determinants recognized by the monoclonal antibodies R2D6 and A2B5 was assessed by reciprocal direct-blocking assays. As shown in Fig. 2 (left (Fig. 2, right ). An irrelevant monoclonal antibody, B5C2, did not block the binding ofeither '5I-A2B5 or 1251-R2D6.
Light and electron microscopic immunocytochemistry. Indirect immunofluorescence studies of cryostat section rat pancreas revealed that R2D6 binds to islets of Langerhans but not to other pancreatic cells (Fig. 3) . R2D6 also recognized mouse and guinea pig islets, but not human or dog islets. Living, dispersed rat islet cells labeled with R2D6 by indirect immunofluorescence exhibited a pattern of rim fluorescence, which suggested a cell surface localization for the antigen recognized by R2D6. In order to identify the precise localization of R2D6 on cells within the pancreatic islets, we labeled unfixed rat islets by indirect immunoperoxidase for electron microscopy. Electron microscopic examination revealed that R2D6 heavily labels the B cell plasma membranes (Fig. 4) first incubated with either an irrelevant antibody or no antibody, exhibited no surface label on any cell. Crossreactivity of R2D6 with other tissues was tested by indirect immunofluorescence studies ofcryostat sections of other organs. As summarized in Table I , R2D6 binds to the adrenal medulla (Fig. 6 A) , the pars distalis (Fig. 6 B) , and the pars tuberalis of the pituitary, and to the myenteric plexus in both the stomach (not shown) and small intestine (Fig. 6 C) , but not to the adrenal cortex, epithelial or smooth muscle cells in the stomach or small intestine, thyroid, thymus, cerebral cortex, cerebellum, RINm5F cells, or to GH3 cells. The pattern of reactivity ofthe previously described anti-islet monoclonal antibody A2B5 (7, 8, 30 ) is similar ( Table I ), except that it also binds to the cerebellum (data not shown) and to thymic epithelial cells and RINm5F cells (references 8 and 31, and present study).
Fluorescence-activated cell sorting. Dispersed rat islet cells, which were labeled with R2D6 by an indirect fluorescent antibody method, were sorted and analyzed by fluorescence-activated flow cytometry. During sorting, the population distributions with respect to cell size (light scatter) and antibody labeling (fluorescence intensity) were analyzed and expressed as two-dimensional dot plots. In the unsorted population (Fig.   7 A) , there was no bimodal distribution on the basis of cell size and, furthermore, there was no correlation between fluorescent intensity and cell size. Fig. 7 B shows that, in the right sort, R2D6-positive (i.e., fluorescent) cells were specifically retrieved and R2D6-negative (i.e., nonfluorescent) cells were excluded. The cell types comprising the R2D6-positive (right sort) and R2D6-negative (left sort) populations were identified ultrastructurally and compared with the unseparated population. As illustrated in Fig. 8 , the R2D6-positive cells were greatly enriched for B cells (88-94% of the right sort), whereas the R2D6-negative cells were enriched for A cells (79-90% ofthe left sort), compared with the unseparated population, regardless of the purity of the starting islet preparation. The recoveries of viable B cells were 28±2.5% (n = 3) of the B cells in the original dispersed islet population; for A cells, the recoveries were 39 and 55% in two experiments.
Antigen identification. The biochemical nature of the plasma membrane antigen recognized by R2D6 was first investigated by determining whether protease or neuraminidase treatment of rat islet cells inhibited subsequent R2D6-binding to the cells. As shown in Fig. 9 , none of the proteases tested affects R2D6-binding; however, neuraminidase treatment reduces subsequent R2D6-binding by 75%. In order to test our initial hypothesis that the antigen recognized by R2D6 is a sialoglycoprotein with a cryptic polypeptide moiety (i.e., inaccessible to proteases), more extensive studies were performed. R2D6-affinity chromatography of radioiodinated islet cell surface proteins and of membrane proteins labeled metabolically with [35S]methionine, and electrophoretic immunoblotting studies failed to reveal the existence of an R2D6-binding plasma membrane protein (data not shown).
A crude islet glycolipid fraction (DME) was then prepared by dichloromethane/methanol (2:1) extraction of islets. Solidphase RIA revealed that the R2D6-binding activity was quantitatively extracted into the solvent phase and was retained when the DME was dried and redissolved in either methanol or in PBS. After the DME was adsorbed to polyvinylchloride plates for RIA, R2D6-binding activity remained insensitive to protease (500 ,ug/ml Pronase at 60°C for 24 h) but was totally destroyed by neuraminidase (1 U/ml at 37°C for 1 h). R2D6-binding activity was unaffected by mild base hydrolysis.
The DME was chromatographed along with purified brain gangliosides on HPTLC plates in chloroform/methanol/2.5 N ammonia (60:40:9). After development of the plates, 5-mm sections of the silica gel were scraped and eluted with methanol.
Solid-phase RIA of R2D6 binding to these fractions revealed that >80% of the R2D6-binding activity migrates consistently as a sharply resolved peak with an Rf of 0.54±0.07 (n = 3), nearly coincident with the purified brain ganglioside, GDla, which was used as a standard (Fig. 10) . Two minor peaks were also present, both variable in magnitude, but never represented >20% of the total R2D6-binding activity. The basis for this apparent heterogeneity remains to be determined. The R2D6-binding activity in the DME eluted in the ganglioside fractions in each of several chromatographic systems. The antigen bound quantitatively to DEAE-Sephacel and was eluted in 0.2 M ammonium acetate in methanol, which demonstrates that it was negatively charged. In addition, the antigen was stable to mild base hydrolysis, which provided evidence that the antigen was not a phospholipid, and bound to a reversephase C-18 Sep-Pak cartridge equilibrated in water. After a methanol wash of the cartridge, the antigen was quantitatively eluted with chloroform/methanol (2:1). The antigen also bound quantitatively to silicic acid in chloroform/methanol (4:1) and was eluted with methanol in the ganglioside fraction.
Discussion
We have demonstrated the existence of a plasma membrane antigen, Ag(R2D6), which is B cell specific within the pancreas and which has an extrapancreatic distribution that is also highly restricted. Ag(R2D6) was identified and characterized using a mouse monoclonal antibody, R2D6, which is an IgM raised against rat pancreatic islet cells. R2D6 also recognizes mouse cally stained (compared with an irrelevant control monoclonal antibody). and guinea pig but not human or canine B cells. The B cell specific localization of Ag(R2D6) within the pancreas was demonstrated by electron microscopic immunocytochemistry and was corroborated by ultrastructural analyses of R2D6-positive and R2D6-negative cells separated by FACS. R2D6 has no effect on glucose-stimulated insulin release in static incubation ofwhole islets or monolayer cultures of rat islets.
We have utilized R2D6 in FACS to prepare highly enriched populations of B cells as well as to prepare A cells from either initially clean islet preparations (Fig. 8 A, experiment 2) or from relatively impure islet preparations (Fig. 8 A, experiments 1 human and bovine brain (7, 39) , also binds to pancreatic islet endocrine cells. Whether these specific oligosaccharide receptors are present in islets as gangliosides remains to be determined. We have shown that the determinant recognized by A2B5 (7, 8, 30, 31) clearly differs from that recognized by R2D6. A2B5 has a broader specificity, both within islets (it binds to A and D cells, in addition to B cells) and in other tissues.
Competitive binding experiments using radioiodinated antibodies show that unlabeled A2B5 inhibits the bindings of labeled R2D6 to rat islets but unlabeled R2D6 does not influence the binding of labeled A2B5 (Fig. 2) . This nonreciprocal inhibition suggests that the determinant recognized by R2D6 is spatially related to the determinant recognized by A2B5, either on the same glycoconjugate or on different "neighboring" species, or that A2B5 recognizes several gangliosides in islets as it does in human brain (39) and that some but not all of these are recognized by R2D6. The relationship of Ag(R2D6) to other B cell plasma membrane glycolipids and to targets for islet cell surface antibodies in diabetes mellitus remains to be defined.
The only extrapancreatic localizations ofAg(R2D6) we have detected so far, by cell-binding RIAs and light microscopic immunocytochemical studies ofa wide, variety ofrat tissues (Table   I) , are in the adrenal medulla, the anterior pituitary, and the myenteric plexus of the gastrointestinal tract. The expression of such 4 highly specialized cell surface antigen by both B cells and these other neurosecretory tissues may be related to a shared physiological property.
It is of special interest that a cell surface determinant on one particular cell-type within the pancreatic islet, viz the B cell, can be shared by other neurosecretory cells. Monoclonal antibodies reactive with multiple organs, including the islets of Langerhans, have been previously produced by fusion ofsplenic leukocytes from reovirus Type I infected mice (40, 41) with mouse myeloma cells, or by fusion of peripheral blood lymphocytes from patients with insulin-requiring diabetes mellitus and other autoimmune abnormalities with mouse or human myeloma cells (42). It remains to be shown, however, whether extrapolation of these observations, and our findings that at least one antigenic determinant is present on cell surfaces in multiple endocrine organs, provide an explanation for circulating antibodies that have multiple organ reactivity and that are found in some patients with recent-onset diabetes mellitus (43, 44 ).
It will be of great interest to know ultimately whether the organ crossreactivity of R2D6 represents the presence of identical antigens in different endocrine tissues or, instead, represents the recognition of a common determinant carried by different, possibly unrelated molecules.
